AstraZeneca PLC (AZNCF) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Drug Manufacturers - General Branche. Der Hauptsitz des Unternehmens ist in Cambridge, United Kingdom. Der aktuelle CEO ist Pascal Claude Roland Soriot.
AZNCF hat IPO-Datum 2009-02-13, 94,300 Vollzeitbeschäftigte, gelistet an der Other OTC, eine Marktkapitalisierung von $294.4B.
AstraZeneca PLC is a global biopharmaceutical company headquartered in Cambridge, United Kingdom, specializing in the discovery, development, manufacturing, and commercialization of prescription medicines. The company maintains a diverse portfolio spanning oncology, cardiovascular and metabolic diseases, respiratory and immunology, and rare diseases, with marketed products including Tagrisso, Lynparza, and Imfinzi for cancer; Farxiga and Crestor for heart and metabolic conditions; Symbicort and Fasenra for respiratory care; and Soliris for rare diseases, among many others. AstraZeneca also markets vaccines and treatments for respiratory syncytial virus, influenza, COVID-19, and other therapeutic areas. The company distributes its medicines through a global network of physicians and representatives across Europe, the Americas, Asia, Africa, and Australasia. AstraZeneca maintains strategic collaborations with leading pharmaceutical and biotechnology partners, including Regeneron Pharmaceuticals for obesity treatments and Ionis Pharmaceuticals for antisense therapies in development.
